Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.

Fidaxomicin 是一种获准用于治疗艰难梭菌感染 (CDI) 的大环抗生素。在英国，非达霉素通常用于严重的 CDI 或复发。在伊丽莎白女王医院伯明翰，对 2017/2018 年期间非达霉素的所有课程进行了审查。38 名患者接受了非达霉素治疗，其中 64% 的患者在第一次轻度 CDI 发作期间给予非达霉素治疗有反应。相反，所有复发性 CDI 患者的非达霉素治疗均失败。使用非达霉素治疗严重 CDI 的结果好坏参半，只有 42% 的患者有反应。这些结果表明，非达霉素最适合作为患者首次发作期间轻度 CDI 的治疗。